B
Bull
Bull · 25%IOVA
$5.72
Szenariopreis
$8.010
-0.243 (-3.03%)Zum Schluss
Loading chart…
- High
- 8.350
- Open
- 8.200
- VWAP
- 8.11
- Vol
- 7.69M
- Mkt Cap
- 2.24B
- Low
- 7.970
- Amount
- 62.39M
- EV/EBITDA, TTM
- -14.85
Iovance Biotherapeutics, Inc. is a commercial biotechnology company. The Company is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its products include Amtagvi and Proleukin. Amtagvi is indicated for the treatment of adult patients with melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor, with or without a MEK inhibitor. It is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. Its TIL therapy includes melanoma, non-small cell lung cancer and gynecologic cancer.
AI analysis of Iovance Biotherapeutics Inc (IOVA)
buyIovance Biotherapeutics Inc is a good buy right now, primarily driven by its recent strong revenue growth and positive market sentiment. The current price is $8.01, with a recent RSI of 56.18 indicating a neutral momentum. The company reported Q2 revenue of $99.3 million, a significant 66% year-over-year increase, which suggests strong demand for its product. Additionally, analysts have raised their price targets, with TD Cowen increasing its target to $10, suggesting a potential upside of 24.84% from the current price. However, the main risk is the company's ongoing net losses, with a net income of -$47.3 million in Q2 2026, which could impact future performance.
Analyst Ratings (7)
+18.60% upside
Buy
7 Buy
0 Hold
0 Sell
Current: 8.01
Tief
1.50
Durchschnitt
9.50
Hoch
17.00
TD Cowen
Buy
$10
2026-08-25
TD Cowen
2026-08-25
Kursziel
$10
Buy
UBS
Neutral
$7
2026-08-20
UBS
2026-08-20
Kursziel
$7
Neutral
Baird
Neutral
$6
2026-08-07
Baird
2026-08-07
Kursziel
$6
Neutral
Citizens
Outperform
$8
2026-08-07
Citizens
2026-08-07
Kursziel
$8
Outperform
Barclays
Overweight
$13
2026-08-07
Barclays
2026-08-07
Kursziel
$13
Overweight
Bewertungskennzahlen
The current forward P/E ratio for Iovance Biotherapeutics Inc (IOVA) is 0.00, compared to its 5-year average forward P/E of -5.66.
Alphio AI Price Scenarios for IOVA
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding IOVA
Event-Zeitleiste
News
5.008-21NewsfilterIovance Grants 240,135 Stock Options to New Employees
2.008-21stocktwitsIovance, Amylyx, and ConocoPhillips Stocks Hit New Highs
9.508-20stocktwitsIOVA Shares Surge as Analysts Raise Price Targets Amid Positive Outlook
9.508-19stocktwitsIovance Biotherapeutics Shares Surge on Positive Catalysts
2.008-19stocktwitsAmylyx, Iovance, and ONEOK Stocks Hit New Highs
IOVA FAQ — answered by Alphio AI
Iovance Biotherapeutics, Inc. is a commercial biotechnology company. The Company is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its products include Amtagvi and Proleukin. Amtagvi is indicated for the treatment of adult patients with melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor, with or without a MEK inhibitor. It is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. Its TIL therapy includes melanoma, non-small cell lung cancer and gynecologic cancer. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Iovance Biotherapeutics Inc is a good buy right now, primarily driven by its recent strong revenue growth and positive market sentiment. The current price is $8.01, with a recent RSI of 56.18 indicating a neutral momentum. The company reported Q2 revenue of $99.3 million, a significant 66% year-over-year increase, which suggests strong demand for its product. Additionally, analysts have raised their price targets, with TD Cowen increasing its target to $10, suggesting a potential upside of 24.84% from the current price. However, the main risk is the company's ongoing net losses, with a net income of -$47.3 million in Q2 2026, which could impact future performance.
7 analysts cover IOVA: 7 rate it Buy, 0 Hold and 0 Sell. The average price target is 9.50.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.